AUSTIN, Texas (MedPage Today) -- The primary endpoint was missed in a phase II trial of arbaclofen in autistic children and adolescents, but positive signs in secondary analyses still give hope for the drug, a researcher said here. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment